Hematology, transfusion and cell therapy最新文献

{"title":"Circulating tumor DNA in diffuse large B-cell lymphoma: analysis of response assessment, correlation with PET/CT and clone evolution.","authors":"Guilherme Duffles, Jersey Heitor da Silva Maués, Fernanda Lupinacci, Luciana Guilhermino Pereira, Elisa Napolitano Ferreira, Leandro Freitas, Fernanda Niemann, Maria Emilia Seren Takahashi, Celso Darío Ramos, Maria de Lourdes L Ferrari Chauffaille, Irene Lorand-Metze","doi":"10.1016/j.htct.2024.07.005","DOIUrl":"10.1016/j.htct.2024.07.005","url":null,"abstract":"<p><strong>Introduction: </strong>Circulating tumor DNA (ctDNA) can be obtained from cell-free DNA (cfDNA) andis a new technique for genotyping, response assessment and prognosis in lymphoma.</p><p><strong>Methods: </strong>Eighteen patients with samples at diagnosis (ctDNA1), after treatment (ctDNA2) and extracted from diagnostic tissue (FFPE) were evaluated.</p><p><strong>Results: </strong>In all patients, at least one mutation in cfDNA was detected at diagnosis. CREBBP was the most frequent mutated gene (67 %). In 12 of the 15 patients with complete remission, the mutation attributed to the disease found at diagnosis cleared with treatment. A reduction in the ctDNA was observed after treatment in 14 patients, 12 of whom achieved complete remission. Correlations were found between the ctDNA at diagnosis and total metabolic tumor volume (r = 0.51; p-value = 0.014) and total lesion glycolysis 2.5 (r = 0.47; p-value = 0.024) by PET at diagnosis and between ctDNA at diagnosis and radiomic features of the lesions with the largest standardized uptake value. There was a strong inverse correlation between ΔctDNA1 and ΔSUVmax by PET/CT (r = -0.8788; p-value = 0.002).</p><p><strong>Conclusion: </strong>Analysis of ctDNA and PET/CT in large B-cell lymphoma are complementary data for evaluating tumor burden and tumor clearance after treatment. Analysis of radiomic data might help to identify tumor characteristics and their changes after treatment.</p>","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":" ","pages":"S241-S249"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NT157 exhibits antineoplastic effects by targeting IRS and STAT3/5 signaling in multiple myeloma.","authors":"Gustavo Nery de Queiroz, Keli Lima, Livia Bassani Lins de Miranda, Eduardo Magalhães Rego, Fabiola Traina, João Agostinho Machado-Neto","doi":"10.1016/j.htct.2024.02.017","DOIUrl":"10.1016/j.htct.2024.02.017","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a prevalent hematological malignancy with high recurrence and no definitive cure. The current study revisits the role of the IGF1/IGF1R axis in MM, introducing a novel inhibitor, NT157. The IGF1/IGF1R pathway is pivotal in MM, influencing cell survival, proliferation, and migration and impacting patient survival outcomes. NT157 targets intracellular proteins such as IRS and STAT proteins and demonstrates antineoplastic potential in hematological malignancies and solid tumors. In the present study, we assessed IGF1R signaling-related gene expression in MM patients and healthy donors, unveiling significant distinctions. MM cell lines displayed varying expression patterns of IGF1R-related proteins. A gene dependence analysis indicated the importance of targeting receptor and intracellular elements over autocrine IGF1. NT157 exhibited inhibitory effects on MM cell viability, clonal growth, cell cycle progression, and survival. Moreover, NT157 reduced IRS2 expression and STAT3, STAT5, and RPS6 activation and modulated oncogenes and tumor suppressors, fostering a tumor-suppressive molecular profile. In summary, our study demonstrates that the IGF1/IGF1R/IRS signaling axis is differentially activated in MM cells and the NT157's capacity to modulate crucial molecular targets, promoting antiproliferative effects and apoptosis in MM cells. NT157 may offer a multifaceted approach to enhance MM therapy.</p>","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":" ","pages":"S112-S121"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140208716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of cerebrospinal fluid chimerism after hematopoietic stem cell transplantation: Case report.","authors":"Yeliz Ogret, Tarik Onur Tiryaki, Cigdem Kekik Cinar, Ipek Yonal Hindilerden, Dilek Ozden Ozluk, Meliha Nalcaci, Fatma Savran Oguz","doi":"10.1016/j.htct.2024.04.129","DOIUrl":"10.1016/j.htct.2024.04.129","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":" ","pages":"S415-S416"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subcutaneous low-dose azacitidine as maintenance therapy following hematopoietic stem cell transplantation for acute myeloid leukemia and high-risk myelodysplastic syndrome-A propensity score matched analysis.","authors":"André Dias Américo, Cinthya Correa Silva, Mariana Nassif Kerbauy, Leonardo Javier Arcuri, Andressa Alice Feitosa Ribeiro, Nelson Hamerschlak, Fábio Pires Souza Santos","doi":"10.1016/j.htct.2024.03.006","DOIUrl":"10.1016/j.htct.2024.03.006","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":" ","pages":"S427-S430"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141879976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optical genome mapping identifies hidden structural variation in acute myeloid leukemia: Two case reports.","authors":"Harmanpreet Singh, Nikhil Shri Sahajpal, Vivek Gupta, Jaspreet Farmaha, Ashutosh Vashisht, Ashis K Mondal, Ravindra Kolhe","doi":"10.1016/j.htct.2024.06.011","DOIUrl":"10.1016/j.htct.2024.06.011","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":" ","pages":"S421-S426"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142690176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Febrile Neutropenia in a Tropical Country.","authors":"Eduardo Magalhães Rego","doi":"10.1016/j.htct.2024.11.118","DOIUrl":"https://doi.org/10.1016/j.htct.2024.11.118","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":"46 Suppl 6 ","pages":"S1-S2"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early bacteremia following allogeneic hematopoietic stem cell transplantation without antibiotic prophylaxis: epidemiology and antimicrobial resistance.","authors":"Nour Ben Abdeljelil, Rihab Ouerghi, Insaf Ben Yaiche, Amine Ben Moussa, Yosra Chebbi, Tarek Ben Othman","doi":"10.1016/j.htct.2024.05.009","DOIUrl":"10.1016/j.htct.2024.05.009","url":null,"abstract":"<p><strong>Objective: </strong>Bacteremia is a serious complication in patients undergoing allogeneic hematopoietic stem cell transplantation. The aim of this study was to determine the frequency, epidemiological profile, and risk factors of bacteremia early after allogeneic hematopoietic stem cell transplantation.</p><p><strong>Methods: </strong>An observational descriptive retrospective study was conducted in patients who received transplants between January 2016 and December 2021. Early bacteremia was defined as blood stream infection occurring between Day 0 and Day 100 after transplantation.</p><p><strong>Results: </strong>Forty episodes of early bacteremia occurred in 36/245 transplanted patients. Fifteen episodes (37.5%) were due to gram-positive bacteria and 25 (62.5%) to gram-negative bacteria. The most frequent species isolated were coagulase negative staphylococci (CoNS) in gram-positive bacteremia (n = 8/15), and Klebsiella species (8/25) and Pseudomonas species (8/25) in gram-negative bacteremia. Twenty-nine episodes of bacteremia (72.5%) occurred during the first 30 days after transplantation with a median time of nine days (range: 0-90 days). Coagulase negative staphylococci were methicillin-resistant in 75% of cases, the only Staphylococcus aureus isolated was methicillin-resistant. All gram-positive bacilli were penicillin-resistant. Gram-negative bacilli were multidrug resistant in 61.5% of cases. In multivariate analysis, bone marrow as source of graft (p-value = 0.02) and cytomegalovirus reactivation (p-value = 0.02) were significantly associated with an increased risk of bacteremia. Mortality attributable to bacteremia was 2.8%. The one-year overall survival was not significantly different between those with and without bacteremia.</p><p><strong>Conclusions: </strong>Bacteremia was more frequent within the first 30 days after transplantation indicating the crucial role of neutropenia. An increase in multidrug resistant gram-negative bacteremia was noted.</p>","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":" ","pages":"S208-S216"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is galactomannan a useful tool for triage and diagnosis of oral invasive aspergillosis?","authors":"Maria Júlia Pagliarone, Lara Maria Alencar Ramos Innocentini, Fernanda Bortolotto, Vanessa Tonetto Marques Galves, Hilton Marcos Alves Ricz, Tatiane Cristina Ferrari, Renato Luiz Guerino Cunha, Belinda Pinto Simões, Leandro Dorigan de Macedo","doi":"10.1016/j.htct.2024.06.005","DOIUrl":"https://doi.org/10.1016/j.htct.2024.06.005","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the accuracy of the galactomannan serum test in diagnosing oral invasive aspergillosis.</p><p><strong>Methods: </strong>This prospective observational study included oncohematological neutropenic patients with suspected invasive aspergillosis, but without signs of pulmonary involvement. These patients underwent nasofibroscopy, biopsy, galactomannan serum testing, and maxillofacial high-resolution computed tomography to diagnose invasive aspergillosis. Patients were divided into two groups: Group 1 consisted of those with proven invasive aspergillosis, while Group 2 included patients without proven invasive aspergillosis. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated.</p><p><strong>Results: </strong>Thirteen patients were included in Group 1 and four in Group 2. The sensitivity, specificity, positive predictive and negative predictive values were 0.69, 1.0, 1.0 and 0.5, respectively. Sensitivity was higher in cases with Aspergillus sinusitis than in cases with exclusive oral lesions (0.77 versus 0.5, respectively). The galactomannan serum test optical density index was higher in Group 1 (2.4; range 0.2-3.5) than in Group 2 (0.2; range: 0.1-0.3; P-value = 0.007.</p><p><strong>Conclusions: </strong>The galactomannan serum test is a valuable tool for screening invasive aspergillosis, especially in cases with nasal or sinus involvement, but biopsy is still the gold standard for diagnosis.</p>","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complex somatic mutation landscape in myeloid cells in a patient with VEXAS syndrome: First Brazilian case report.","authors":"Fabíola Reis de Oliveira, Adriane Souza Lima, Carlos Roberto Faria, Thaise Oliveira Quaresma, Marcio M Mourani, Lauro Wichert-Ana, Paulo Louzada, Fernanda Gutierrez-Rodrigues, Neal S Young, Rodrigo T Calado","doi":"10.1016/j.htct.2024.05.013","DOIUrl":"https://doi.org/10.1016/j.htct.2024.05.013","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From the mechanism of action to clinical management: A review of cardiovascular toxicity in adult treated with CAR-T therapy.","authors":"Frank Nunes, Breno Moreno de Gusmão, Franciely Bueno Wiginesk, Euler Manenti, Juliana Soares, Mizianne Garcia Freitas, Juliane Dantas Seabra-Garcez, Alexandre Manoel Varela, João Pedro Passos Dutra, Bruno Cesar Bacchiega, Tânia Félix Lorenzato da Fonseca Peixoto, Carolina Maria Pinto Domingues de Carvalho E Silva, Renato D Lopes, Ariane Vieira Scarlatelli Macedo","doi":"10.1016/j.htct.2024.06.008","DOIUrl":"https://doi.org/10.1016/j.htct.2024.06.008","url":null,"abstract":"<p><p>Chimeric antigen receptor T-cell therapy represents an innovative approach to immunotherapy and currently stands out, particularly for oncohematological patients refractory to traditional treatments. Ongoing trials are further expanding its clinical use for new oncological and non-oncological indications, potentially leading to newer treatment options soon. This new approach, however, also presents challenges, including cardiovascular toxicity. Little is reported in pivotal studies, and some recent retrospective observations suggest a non-negligible incidence of side effects with presentation ranging from mild adverse cardiovascular events to fatal complications in which, in most cases, there is a direct or indirect association with cytokine release syndrome. In this literature review, the hypotheses of an important interface between cytokine release syndrome and cardiotoxicity by chimeric antigen receptor T-cell therapy will be addressed, as will current knowledge about risk factors for cardiotoxicity and recommendations for pre-therapy evaluation, post-infusion monitoring and clinical management of these complications.</p>","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}